The Food and Drug Administration Friday approved the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” said Tim Stenzel, M.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday approved a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
A new report from the National Academies of Sciences, Engineering, and Medicine calls for developing better diagnostics, vaccines and treatments to enhance U.S…
Headline
U.S. health care organizations should immediately transition away from using certain unauthorized plastic syringes made in China by Jiangsu Caina Medical Co.…
Headline
AHA March 18 shared with the House Ways and Means Committee its proposals to strengthen access to timely emergency medical care, particularly in rural and…
Headline
The AHA and other founding members of the Common Health Coalition March 13 committed to action in four priority areas: coordination between health care and…
Headline
AHA has released videos, social media posts and other new resources highlighting the importance of patient safety for Patient Safety Awareness Week, March 10-…
Chairperson's File
This week is Patient Safety Awareness Week. It’s an annual recognition to inspire action and raise awareness to improve the safety of our health care system…